Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Vivos Q2 2026 revenue growth and margin expansion amid expansion plans

Aug 14, 2026, 4:31 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Despite revenue growth and margin gains, persistent cash burn and a stockholders’ deficit heighten dilution risk; near-term price may be pressured until visibility on financing or partnerships improves.

AI summary

What happened, with direct paths to the underlying reporting

Vivos Therapeutics reported Q2 2026 results showing stronger revenue and margin amid capacity expansion and AI software rollout. Management cited rising referrals in Nevada, pediatric program gains, and pending multi-center cardiology partnerships in Florida and Arizona as catalysts for near-term revenue growth, though the company remains cash-negative with liquidity and equity concerns.

Q2 2026 revenue up 35% YoY to $5.2M.
Gross margin improved to 57% (Q2) and 58% (six months).
Cash and equity stressed: cash $1.8M, equity deficit $3.8M.
Facilities and production expanded; AI software conversion at SCN underway.
Pending cardiology partnerships could unlock revenue in key markets.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.